Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry

Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry

Abstract Background Immune related adverse events (irAEs) are associated with immunotherapy for cancer and while results suggest improvement in tumor control and overall survival in those experiencing irAEs, the long-term impact is debated. We evaluated irAE reports related to high dose interleukin-...

Full description

Bibliographic Details
Main Authors: Brendan Curti, Gregory A. Daniels, David F. McDermott, Joseph I. Clark, Howard L. Kaufman, Theodore F. Logan, Jatinder Singh, Meenu Kaur, Theresa L. Luna, Nancy Gregory, Michael A. Morse, Michael K. K. Wong, Janice P. Dutcher
Format: Article
Language:English
Published: BMJ Publishing Group 2017-12-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Immune-related adverse events
Interleukin-2
Renal cell carcinoma
Melanoma
Survival
PROCLAIMSM
Online Access:http://link.springer.com/article/10.1186/s40425-017-0307-5

Internet

http://link.springer.com/article/10.1186/s40425-017-0307-5

Similar Items